(APLM) Long Term Investment Analysis

Stock Information for Apollomics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Apollomics Inc.

Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
Apollomics' Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split
Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024
Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.